Skip to content

Study · Randomized controlled trial · n = 192 · 1999

3 results

Impact of nafarelin and leuprolide for endometriosis on quality of life and subjective clinical measures.

Zhao SZ, Kellerman LA, Francisco CA, Wong JM

The Journal of reproductive medicine1 Dec 1999Cited by 7 (Europe PMC)

PMID10649809 (opens in a new tab)PepBankPUB-10649809
Publisher pageAsk about this study
Jump to 3 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study3

3 results from studies that gave the peptide. 3 results from people.

  1. 01HumanRandomized controlled trialSafety outcome

    In women with endometriosis, nafarelin was associated with significantly fewer days with moderate or severe hot flashes than leuprolide during treatment (P < .05).

    In plain wordsIn women with endometriosis, nafarelin was linked to fewer days with moderate or severe hot flashes than leuprolide.

    Peptide
    Nafarelin
    Outcome
    DecreaseDays with moderate or severe hot flashes
    Study

    n = 192

    Comparator
    Leuprolide
    Outcome group
    Adverse events · Reproductive and sexual health
    Studied dose
    Dose not stated · six monthsAs given in this study (human).

    Source sentences

    Summary
    Nafarelin was associated with significantly fewer days with moderate or severe hot flashes than leuprolide during treatment (P < .05)
    2 context sentences
    Summary · context
    A randomized, multicenter study was conducted on 192 women with endometriosis.
    Summary · context
    Patients received nafarelin or leuprolide for six months and were followed for up to six months after treatment.
  2. 02HumanRandomized controlled trialSafety outcome

    In women with endometriosis, nafarelin was associated with significantly fewer moderate or severe hypoestrogenic symptoms than leuprolide overall at three months of treatment (P < .05).

    In plain wordsIn women with endometriosis, nafarelin was linked to fewer moderate or severe low-estrogen symptoms than leuprolide at three months.

    Peptide
    Nafarelin
    Outcome
    DecreaseModerate or severe hypoestrogenic symptoms
    Study

    n = 192

    Comparator
    Leuprolide
    Outcome group
    Adverse events · Reproductive and sexual health
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Nafarelin was associated with significantly fewer days with moderate or severe hot flashes than leuprolide during treatment (P < .05) and with significantly fewer moderate or severe hypoestrogenic symptoms overall at three months of treatment (P < .05).
    2 context sentences
    Summary · context
    A randomized, multicenter study was conducted on 192 women with endometriosis.
    Summary · context
    Patients received nafarelin or leuprolide for six months and were followed for up to six months after treatment.
  3. 03HumanObservational studyEfficacy outcome

    In women with severe baseline endometriosis symptoms, nafarelin was linked to greater posttreatment quality-of-life improvement than leuprolide (P < .01).

    In plain wordsIn women with severe baseline endometriosis symptoms, nafarelin was linked to greater quality-of-life improvement after treatment than leuprolide.

    Peptide
    Nafarelin
    Outcome
    IncreasePosttreatment quality of life in severe baseline symptoms
    Study

    n: not reported in source

    Comparator
    Leuprolide
    Outcome group
    Quality of life · Reproductive and sexual health
    Studied dose
    Dose not stated · six monthsAs given in this study (human).

    Source sentences

    Summary
    Those with severe symptoms of endometriosis at baseline and taking nafarelin had a significantly greater improvement in QOL at the last posttreatment visit than those receiving leuprolide (P < .01).
    2 context sentences
    Summary · context
    A randomized, multicenter study was conducted on 192 women with endometriosis.
    Summary · context
    Patients received nafarelin or leuprolide for six months and were followed for up to six months after treatment.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 3Current

    28 Oct 2026, 02:03 UTC

    Study results updated

  2. Version 2

    27 Oct 2026, 16:37 UTC

    Study data updated · source update from Europe PMC

  3. Version 1

    27 Oct 2026, 16:36 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.